Abstract:On December 14, 2006, the Food and Drug Administration (FDA) proposed two new regulations in the Federal Register amending current regulations governing expanded access to investigational drugs for treatment use and charging for investigational drugs. The proposals come at a time when FDA has found itself under new pressure to provide seriously ill patients with early access to investigational drugs outside the framework of clinical trials. In recent years, patient advocacy groups have filed citizen petitions with FDA asking the agency to provide specific criteria to patients and sponsors seeking expanded access or to create an early approval mechanism to permit easier access to investigational therapies. Further, FDA has seen proposed federal legislation intended to ensure early patient access to investigational treatments and nearly lost a lawsuit in federal court in which terminally ill patients sought a fundamental right of access to investigational therapies under the Due Process Clause of the Constitution. The proposed rules seek to assuage patient activists, physicians, drug sponsors and other critics who contend that FDA must strike an appropriate balance between allowing patient access to promising treatments while protecting against undue risk and safeguarding the clinical trials process. Although FDA heralded the announcement of the rules as a key step forward to improving patient access, the proposal does not expand access beyond measures currently available under longstanding agency practice and, in fact, creates new regulatory barriers and disincentives to industry participation in expanded access programs. This article examines the proposal in light of historical agency regulation and recent pressures to expand access. Section II describes the historical development of FDA's statutory authority to regulate drugs and the traditional new drug approval process. Section III describes the various methods through which FDA has allowed expanded access to investigational treatments since 1962. Section IV recounts various recent pressures on FDA to reform its expanded access procedures and describes the context in which FDA's recent proposal arises. Section V examines the changes proposed in both the proposed rules to expand access to investigational treatment and charging for investigational drugs. Section VI evaluates the rules and argues that the proposal will fail to expand access for patients because new restrictions on charging provide no incentive for industry participation and the proposed regulations create increased regulatory barriers to access inconsistent with FDA's statutory mandate

Follow-on biologics: data exclusivity and the balance between innovation and competition

Establishing healthy pharmaceutical regulations on statutory exclusivity: Lessons from the experience in the European Union, Canada, South Korea, Australia, and the United States

The Case for Disclosure of Biologics Manufacturing Information

Patent Claim Scope and Biosimilar Competition in the US and EU

Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it

Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act

The next generation of rare disease drug policy: ensuring both innovation and affordability

Patent Cliffs in the Era of Complex Therapies and Biologics

Development and regulation of biosimilars: current status and future challenges

Dynamics of biological markets with multiple biosimilar competitors in the United States

FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform

Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies

The quest for market exclusivity in biotechnology: navigating the patent minefield

The Effect of Government Policy on Pharmaceutical Drug Innovation

Paper Promises for Drug Innovation

Can next-generation antibodies offset biosimilar competition?

Expediting treatments in the 21st century: orphan drugs and accelerated approvals

Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA

AMCP Partnership Forum: Biosimilars-policy, practice, and postmarketing surveillance to support treatment and coverage decisions

Continuing trends in U.S. brand-name and generic drug competition

Postapproval Innovation For Oncology Drugs And The Inflation Reduction Act